Financials data is unavailable for this security.
View more
Year on year Fulgent Genetics Inc 's revenues fell -53.27% from 618.97m to 289.21m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a gain of 143.40m to a loss of 167.83m.
| Gross margin | 39.10% |
|---|---|
| Net profit margin | -58.73% |
| Operating margin | -65.91% |
| Return on assets | -13.20% |
|---|---|
| Return on equity | -13.66% |
| Return on investment | -13.96% |
More ▼
Cash flow in USDView more
In 2023, Fulgent Genetics Inc increased its cash reserves by 22.60%, or 17.97m. Cash Flow from Investing totalled 38.90m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 27.00m in cash from operations while cash used for financing totalled 47.79m.
| Cash flow per share | -4.84 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 37.42 |
|---|---|
| Tangible book value per share | 32.10 |
More ▼
Balance sheet in USDView more
| Current ratio | 5.27 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.0008 |
|---|---|
| Total debt/total capital | 0.0008 |
More ▼
